Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

OTCPK:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > In my opinion

<< Previous

Bullboard Posts

Next >>

Post by Duster340on Oct 05, 2023 11:06am

198 Views

Post# 35671049

In my opinion

i think we could see insider buying soon (between now and year end), when management gets the results of the PK/PD study, if they are possitive what better time for them to buy when the stock is close to 52 week lows and the first of several potential catalysts. if this happens get ready to load up.
glta

<< Previous

Bullboard Posts

Next >>

Mullen Group: Navigates market challenges towards success